Who
David Henry Mack
President and CEO
Company insider
Files Form 4 as: President and CEO, PMV Pharmaceuticals; Director, Aduro Biotech; 10% owner, Talphera.
In numbers
- Trades disclosed
- 76
- Buys
- 1
- Sells
- 6
- Bought
- $3.4M
- Sold
- $1.6M
- Companies
- 3
- Companies where not an officer
- 2
- First trade
- 16 Feb 2011
- Last trade
- 5 Mar 2026
- Last filed
- 9 Mar 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 5 Mar 2026filed 9 Mar 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —744,960 at $0.00 | filing |
| 5 Mar 2026filed 9 Mar 2026 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —744,960 at $0.00 | filing |
| 27 Oct 2025filed 29 Oct 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —220,643 at $0.00 | filing |
| 27 Oct 2025filed 29 Oct 2025 | PMVP PMV PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $302K220,643 at $1.37 | filing |
| 1 Jul 2025filed 3 Jul 2025 | PMVP PMV PharmaceuticalsBiotechnology | SEC FORM 4 Sold | $62K58,411 at $1.06 | filing |
| 3 Mar 2025filed 5 Mar 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —800,000 at $0.00 | filing |
| 3 Jan 2025filed 22 Jan 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —17,709 at $0.00 | filing |
| 3 Jan 2025filed 22 Jan 2025 | PMVP PMV PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $9,38617,709 at $0.53 | filing |
| 3 Dec 2024filed 22 Jan 2025 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code M | —91,750 at $0.00 | filing |
| 3 Dec 2024filed 22 Jan 2025 | PMVP PMV PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $49K91,750 at $0.53 | filing |
| 13 Aug 2024filed 3 Oct 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —134,584 | filing |
| 13 Aug 2024filed 3 Oct 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —249,600 | filing |
| 13 Aug 2024filed 3 Oct 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —384,184 | filing |
| 13 Aug 2024filed 3 Oct 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code D | —330,000 | filing |
| 13 Aug 2024filed 3 Oct 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —330,000 | filing |
| 18 Jan 2024filed 22 Jan 2024 | PMVP PMV Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —519,915 at $0.00 | filing |
| 18 Jan 2024filed 22 Jan 2024 | PMVP PMV PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —163,890 at $0.00 | filing |
| 10 Nov 2023filed 13 Nov 2023 | PMVP PMV PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —85,307 at $0.00 | filing |
| 10 Nov 2023filed 13 Nov 2023 | PMVP PMV PharmaceuticalsBiotechnology | SEC FORM 4 Code G | —85,307 at $0.00 | filing |
| 18 Oct 2023filed 13 Nov 2023 | PMVP PMV PharmaceuticalsBiotechnology | SEC FORM 4 Code M | $105K198,407 at $0.53 | filing |
News
Evolus (NASDAQ:EOLS) & Talphera (NASDAQ:TLPH) Financial ComparisonTLPH · dailypolitical.com · 13 Oct 2026
0 headlines in the last 90 days name David Henry Mack; 1 article from the last 14 days about the 2 companies they traded most, at most three about any one of them.